Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Cash from Operations (2021 - 2025)

Historic Cash from Operations for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to -$30.4 million.

  • Amylyx Pharmaceuticals' Cash from Operations rose 2694.73% to -$30.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$154.4 million, marking a year-over-year decrease of 6242.64%. This contributed to the annual value of -$167.6 million for FY2024, which is 150655.26% down from last year.
  • Amylyx Pharmaceuticals' Cash from Operations amounted to -$30.4 million in Q3 2025, which was up 2694.73% from -$25.2 million recorded in Q2 2025.
  • Amylyx Pharmaceuticals' Cash from Operations' 5-year high stood at $13.6 million during Q4 2023, with a 5-year trough of -$66.6 million in Q2 2024.
  • Over the past 5 years, Amylyx Pharmaceuticals' median Cash from Operations value was -$28.2 million (recorded in 2021), while the average stood at -$26.6 million.
  • In the last 5 years, Amylyx Pharmaceuticals' Cash from Operations skyrocketed by 12726.72% in 2023 and then crashed by 804396.73% in 2025.
  • Over the past 5 years, Amylyx Pharmaceuticals' Cash from Operations (Quarter) stood at -$28.2 million in 2021, then crashed by 75.96% to -$49.7 million in 2022, then surged by 127.27% to $13.6 million in 2023, then crashed by 535.45% to -$59.0 million in 2024, then soared by 48.54% to -$30.4 million in 2025.
  • Its last three reported values are -$30.4 million in Q3 2025, -$25.2 million for Q2 2025, and -$39.8 million during Q1 2025.